Advertisement

Breast Cancer

, Volume 18, Issue 1, pp 37–41 | Cite as

Immunohistochemical expression of epidermal growth factor receptor in breast cancer

  • Tadahiro Nozoe
  • Emiko Mori
  • Tomohiro Iguchi
  • Akinori Egashira
  • Eisuke Adachi
  • Akito Matsukuma
  • Takahiro Ezaki
Original Article

Abstract

Background

Molecular-targeting drugs able to treat breast cancer expressing epidermal growth factor receptor (EGFR) would be clinically valuable. The aim of the current study was to determine the further significance of immunohistochemical expression of EGFR in breast cancer.

Methods

The immunohistochemical expression of EGFR was examined in 37 women with breast cancer who had been treated with surgical resection. Relationship of EGFR expression and clinicopathological characteristics was investigated.

Results

EGFR expression proved to be comparatively more frequent among triple-negative (estrogen receptor negative, progesterone receptor negative, and human epidermal growth factor receptor 2 negative) breast cancers (P = 0.067).

Conclusions

Knowledge of a patient’s immunohistochemical EGFR expression, which could be one of the key molecular findings related to molecular-targeting therapy, might be useful information to treat triple-negative breast cancer.

Keywords

EGFR Immunohistochemical expression Breast cancer Triple negative cancer 

Abbreviations

EGFR

Epidermal growth factor receptor

TNBC

Triple negative breast cancer

TBS

Tris-buffered saline

Notes

Acknowledgments

The authors thank our pathology technicians, Mr. Y. Sei and Mrs. K. Matsumoto, for their assistance and cooperation.

References

  1. 1.
    Guillamo JS, de Boüard S, Valable S, Marteau L, Leuraud P, Marie Y, et al. Molecular mechanisms underlying effects of epidermal growth factor receptor inhibition on invasion, proliferation, and angiogenesis in experimental glioma. Clin Cancer Res. 2009;15:3697–704.CrossRefPubMedGoogle Scholar
  2. 2.
    Wang KL, Wu TT, Choi IS, Wang H, Resetkova E, Correa AM, et al. Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Cancer. 2007;109:658–67.CrossRefPubMedGoogle Scholar
  3. 3.
    Gamboa-Dominguez A, Dominguez-Fonseca C, Quintanilla-Martinez L, Reyes-Gutierrez E, Green D, Angeles-Angeles A, et al. Epidermal growth factor receptor expression correlates with poor survival in gastric adenocarcinoma from Mexican patients: a multivariate analysis using a standardized immunohistochemical detection system. Mod Pathol. 2004;17:579–87.CrossRefPubMedGoogle Scholar
  4. 4.
    Putti TC, To KF, Hsu HC, Chan AT, Lai GM, Tse G, et al. Expression of epidermal growth factor receptor in head and neck cancers correlates with clinical progression: a multicentre immunohistochemical study in the Asia-Pacific region. Histopathology. 2002;41:144–51.CrossRefPubMedGoogle Scholar
  5. 5.
    Psyrri A, Kassar M, Yu Z, Bamias A, Weinberger PM, Markakis S, et al. Effect of epidermal growth factor receptor expression level on survival in patients with epithelial ovarian cancer. Clin Cancer Res. 2005;11:8637–43.CrossRefPubMedGoogle Scholar
  6. 6.
    Buchholz TA, Tu X, Ang KK, Esteva FJ, Kuerer HM, Pusztai L, et al. Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy. Cancer. 2005;104:676–81.CrossRefPubMedGoogle Scholar
  7. 7.
    Tsutsui S, Ohno S, Murakami S, Hachitanda Y, Oda S. Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer. Breast Cancer Res Treat. 2002;71:67–75.CrossRefPubMedGoogle Scholar
  8. 8.
    Nogi H, Kobayashi T, Suzuki M, Tabei I, Kawase K, Toriumi Y, et al. EGFR as paradoxical predictor of chemosensitivity and outcome among triple-negative breast cancer. Oncol Rep. 2009;21:413–7.PubMedGoogle Scholar
  9. 9.
    Cleator S, Heller W, Coombes RC. Triple-negative breast cancer: therapeutic options. Lancet Oncol. 2007;8:235–44.CrossRefPubMedGoogle Scholar
  10. 10.
    Japanese Breast Cancer Society. General rules for clinical and pathological recording of breast cancer. Breast Cancer. 2005;12:S12–4.CrossRefGoogle Scholar
  11. 11.
    Kammerer U, Kapp M, Gassel AM, Richter T, Tank C, Dietl J, et al. A new rapid immunohistochemical staining technique using the EnVision antibody complex. J Histochem Cytochem. 2001;49:623–30.PubMedGoogle Scholar
  12. 12.
    Guler G, Huebner K, Himmetoglu C, Jimenez RE, Costinean S, Volinia S, et al. Fragile histidine triad protein, WW domain-containing oxidoreductase protein Wwox, and activator protein 2gamma expression levels correlate with basal phenotype in breast cancer. Cancer. 2009;115:899–908.CrossRefPubMedGoogle Scholar
  13. 13.
    Capdevila J, Elez E, Macarulla T, Ramos FJ, Ruiz-Echarri M, Tabernero J. Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment. Cancer Treat Rev. 2009;35:354–63.CrossRefPubMedGoogle Scholar
  14. 14.
    Magkou C, Nakopoulou L, Zoubouli C, Karali K, Theohari I, Bakarakos P, et al. Expression of the epidermal growth factor receptor (EGFR) and the phosphorylated EGFR in invasive breast carcinomas. Breast Cancer Res. 2008;10:49–55.CrossRefGoogle Scholar
  15. 15.
    Talley L, Chhieng DC, Bell WC, Grizzle WE, Frost AR. Immunohistochemical detection of EGFR, p185(erbB-2), Bcl-2 and p53 in breast carcinomas in pre-menopausal and post-menopausal women. Biotech Histochem. 2008;83:5–14.CrossRefPubMedGoogle Scholar
  16. 16.
    Yoshimoto M, Tada K, Hori H, Morota A, Tanabe M, Nishimura S, et al. Improvement in the prognosis of Japanese breast cancer patients from 1946 to 2001—an institutional review. Jpn J Clin Oncol. 2004;34:457–62.CrossRefPubMedGoogle Scholar
  17. 17.
    Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer. 2007;109:25–32.CrossRefPubMedGoogle Scholar
  18. 18.
    Irvin WJ Jr, Carey LA. What is triple-negative breast cancer? Eur J Cancer. 2008;44:2799–805.CrossRefPubMedGoogle Scholar
  19. 19.
    Cho EY, Han JJ, Choi YL, Kim KM, Oh YL. Comparison of Her-2, EGFR and cyclin D1 in primary breast cancer and paired metastatic lymph nodes: an immunohistochemical and chromogenic in situ hybridization study. J Korean Med Sci. 2008;23:1053–61.CrossRefPubMedGoogle Scholar
  20. 20.
    Corkery B, Crown J, Clynes M, O’Donovan N. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. Ann Oncol. 2009;20:862–7.CrossRefPubMedGoogle Scholar
  21. 21.
    Oliveras-Ferraros C, Vazquez-Martin A, López-Bonet E, Martín-Castillo B, Del Barco S, Brunet J, et al. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer. Int J Oncol. 2008;33:1165–76.PubMedGoogle Scholar
  22. 22.
    Gholam D, Chebib A, Hauteville D, Bralet MP, Jasmin C. Combined paclitaxel and cetuximab achieved a major response on the skin metastases of a patient with epidermal growth factor receptor-positive, estrogen receptor-negative, progesterone receptor-negative and human epidermal growth factor receptor-2-negative (triple-negative) breast cancer. Anticancer Drugs. 2007;18:835–7.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Breast Cancer Society 2010

Authors and Affiliations

  • Tadahiro Nozoe
    • 1
  • Emiko Mori
    • 1
  • Tomohiro Iguchi
    • 1
  • Akinori Egashira
    • 1
  • Eisuke Adachi
    • 1
  • Akito Matsukuma
    • 1
  • Takahiro Ezaki
    • 1
  1. 1.Department of SurgeryFukuoka Higashi Medical CenterKogaJapan

Personalised recommendations